MammoLink Adds cmAngio to Breast Imaging Program

The Florida provider will use CureMetrix's FDA-cleared tool to flag breast arterial calcifications from routine screening mammograms.

Updated on Nov. 2, 2026 in Cancer

Photograph of a plain white mobile medical trailer parked on a paved lot beside a low stucco building under a palm tree in Florida. — MammoLink, a Florida mobile mammography provider, is adding CureMetrix's FDA-cleared cmAngio tool to flag breast arterial calcifications from routine screening mammograms. AI Illustration. Upload story photo >

MammoLink, a physician-owned provider of mobile 3D mammography, has added CureMetrix's cmAngio to its breast imaging program. The FDA-cleared solution detects, quantifies and contextualizes breast arterial calcifications (BAC) from the routine screening mammogram.

Why it matters

Florida residents receiving screening mammograms through MammoLink's mobile services could have BAC identified without additional imaging, radiation or procedures. The addition gives the provider a new screening capability within its existing workflow.

The tool works from the standard screening mammogram with no added radiation or procedures, based on the FDA-cleared function described by the provider. Clinical outcome figures and patient volumes were not reported, and how often BAC findings will be acted on remains unresolved.

The players

MammoLink

MammoLink is a physician-owned provider of mobile 3D mammography services operating across Florida.

CureMetrix

CureMetrix is the developer of cmAngio, an FDA-cleared software tool for analyzing breast imaging.

The details

CureMetrix's cmAngio identifies breast arterial calcifications from the routine screening mammogram without changing standard mammography workflows. MammoLink, which delivers screening mammography to communities, employers, physician offices and healthcare partners across Florida, is integrating the tool into its services.

Screening Extension

The addition extends cmAngio from its FDA clearance into a mobile screening program serving Florida communities without requiring new imaging hardware. It places BAC detection inside a routine mammogram, the same exam used for cancer screening.

Patients whose screening mammograms are performed with this tool may have BAC reported alongside their standard results, which could prompt a conversation with their clinician. The extraction does not describe any change to cost, scheduling or insurance coverage.

The takeaway

Patients getting a screening mammogram in Florida can ask whether the provider reviews breast arterial calcifications and what that finding means for their heart and breast health. Screening results that include BAC may be worth discussing with a primary care physician.